Migraine

Enlyte Drug Trends Report Indicates Significant Drop of Opioid Use in Comp

Retrieved on: 
Tuesday, April 30, 2024
Prescription, MBA, Migraine, Fluticasone furoate/umeclidinium bromide/vilanterol, Chronic pain, Doctor of Pharmacy, SAN, Overalls, Pharmaceutical industry

SAN DIEGO, April 30, 2024 /PRNewswire/ -- Efforts by workers' comp regulators and professionals to control opioid prescriptions and distribution are resulting in one of the largest drops in utilization the workers' comp industry has seen in years, according to researchers who published part one of Enlyte's 2024 Annual Pharmacy Solutions Drug Trends Report today.

Key Points: 
  • Each year Enlyte researchers analyze drug utilization and spending trends in workers' comp to provide the industry with new insights in pharmacy management.
  • Enlyte's 2024 series reflects on trends clients experienced in 2023, with an overview of both in- and out-of-network prescriptions.
  • Among opioid categories, the report indicates decreases in utilization, including sustained-released opioids, which dropped by more than 10% in 2023, as supported by prescribing guidelines.
  • Researchers also noted per claim drops in overall drug cost and utilization in workers' comp among therapeutic classes ranked by cost in 2023.

Oral Thin Films Market Projected to Reach $7.65 Billion by 2028 with a Robust CAGR of 13.6% - Expansive Growth in Asia-Pacific Region and Noteworthy Trends in Drug Delivery Technologies - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 25, 2024
Health, Pharmaceutical, Migraine, Schizophrenia, Medicine, Research, Administration, Pharmaceutical industry

The global oral thin films market is experiencing a dynamic upsurge, expected to grow significantly to $7.65 billion by 2028, advancing at a compound annual growth rate (CAGR) of 13.6%.

Key Points: 
  • The global oral thin films market is experiencing a dynamic upsurge, expected to grow significantly to $7.65 billion by 2028, advancing at a compound annual growth rate (CAGR) of 13.6%.
  • This remarkable growth trajectory is underpinned by the versatile and patient-friendly nature of oral thin films, which is greatly influencing their adoption across a diverse range of therapeutic areas.
  • Innovation at the Forefront:
    Strategic innovations by leading market participants are propelling the oral thin films industry forward.
  • North America leads the oral thin films market due to advanced healthcare infrastructure and a pronounced focus on research and development.

AndHealth Partners with PrimaryOne Health to Address Health Inequities by Offering In-House Specialty Care

Retrieved on: 
Tuesday, April 23, 2024
General Health, Professional Services, Hospitals, Family, DEI (Diversity, Equity and Inclusion), Dental, Consumer, Health, Health Technology, Health Insurance, Telemedicine, Virtual Medicine, Other Health, Women, Human Resources, Pharmaceutical, Optical, Practice Management, Health equity, CHC, Rheumatology, Pediatrics, Partnership, Social, Community health center, Community, Patient, Neurology, Rheumatoid arthritis, Psoriasis, Headache, Movement, Face, Health system, Migraine, Sleep, Dermatology, Nursing

AndHealth announced today its partnership with PrimaryOne Health to bring in-house whole-person specialty care to the communities they serve.

Key Points: 
  • AndHealth announced today its partnership with PrimaryOne Health to bring in-house whole-person specialty care to the communities they serve.
  • PrimaryOne Health supports Franklin County and Pickaway County as the oldest and largest Community Health Center (CHC) in central Ohio.
  • Since 1997, PrimaryOne Health has delivered whole-person care to the medically underserved communities of central Ohio including primary care, OB/GYN, dental, vision, behavioral health, and pediatrics.
  • This comprehensive, whole-person approach to specialty care enables patients to have better health outcomes and receive care directly within their medical home.

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China

Retrieved on: 
Thursday, April 11, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Fear, Hospital, Safety, Nausea, Teva, TEVA, Doctor of Philosophy, Depression, Migraine, Light, Family, Vomiting, Patient, Aes, Molina Healthcare, Medication, Quality of life, Anxiety, Teva Pharmaceuticals, Sound

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a Phase 3 study evaluating the efficacy and safety of AJOVY for the prevention of migraine in adult Chinese patients.

Key Points: 
  • Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a Phase 3 study evaluating the efficacy and safety of AJOVY for the prevention of migraine in adult Chinese patients.
  • In the study, AJOVY achieved primary endpoint and all secondary endpoints, significantly reducing the number of migraine days experienced per month, demonstrating superior efficacy over placebo.
  • Study data also show AJOVY was safe and well tolerated with no emerging safety signals.
  • Additional findings from this study are planned for presentation at a medical meeting later this year.

Thirty Madison's Nurx and Cove partner with Talkspace to expand mental health support for more than half a million women

Retrieved on: 
Thursday, April 25, 2024
Health, Anxiety, Migraine, Mental health, Partnership, Talkspace, Patient, Dermatology, Depression, Mental, Woman, Nursing

NEW YORK , April 25, 2024 /PRNewswire/ -- Thirty Madison, the specialty telemedicine company operating Keeps, Cove, and Nurx, today announced a partnership with Talkspace, a  leading online behavioral health company, to expand comprehensive mental health offerings for more than half a million women.

Key Points: 
  • NEW YORK , April 25, 2024 /PRNewswire/ -- Thirty Madison , the specialty telemedicine company operating Keeps, Cove, and Nurx, today announced a partnership with Talkspace , a  leading online behavioral health company, to expand comprehensive mental health offerings for more than half a million women.
  • Talkspace will serve as the recommended therapy partner for Thirty Madison brands Nurx , the leader in specialty, comprehensive care in women's health, and Cove , the largest virtual clinic treating migraine.
  • "Since we began offering Nurx patients mental health treatment in 2022, we have seen consistently strong and increasing demand.
  • By joining forces, Thirty Madison and Talkspace aim to address the growing demand with mental health experts and asynchronous care, readily available for patients whenever they need it.

PCORI announces $150 million in funding for new health research

Retrieved on: 
Tuesday, April 23, 2024
Post-traumatic stress disorder, CER, Research, Violence, Science, Patient, MPH, DSM-IV codes, MSCE, Migraine, Asthma, Heart failure, Pharmaceutical industry

WASHINGTON, April 23, 2024 /PRNewswire/ -- The Patient-Centered Outcomes Research Institute (PCORI) today announced the approval of funding awards totaling more than $150 million to support new patient-centered comparative clinical effectiveness research (CER) studies, research to strengthen the rigor and quality of patient-centered CER and a project to implement the findings of PCORI-funded research into practice.

Key Points: 
  • Two other large studies will compare health system strategies to improve hypertension control, and another will evaluate the effectiveness of medications used for migraine prevention.
  • "As a leading funder of patient-centered comparative clinical effectiveness research, PCORI recognizes the evidence generated from PCORI-funded research helps patients and those who care for them make informed decisions about which health care options will work best for them," said PCORI Executive Director Nakela L. Cook, M.D., MPH.
  • "PCORI also funds projects to encourage uptake of results from PCORI-funded comparative clinical effectiveness research to promote trustworthy findings reaching those whom they can help the most."
  • Since 2010, PCORI has invested more than $4.5 billion to fund patient-centered CER and research-related projects.

Rosy Debuts New Content Focused on Menopause and Migraine Education

Retrieved on: 
Thursday, April 18, 2024
Physician, Webby, PCOS, Woman, Health, MD, Endometriosis, Webby Awards, Migraine, Female, Sensation, Patient, Diagnosis, OB, Libido, Personal lubricant, Quality of life, Menopause, Knowledge, Disability, Birth control

DALLAS, April 18, 2024 /PRNewswire-PRWeb/ -- Rosy, the Webby Award winning app-based platform that addresses common health concerns for women throughout their lifespans, announces an expanded focus beyond sexual wellness. Through its new sponsorship from Pfizer, one of the world's premier biopharmaceutical companies, Rosy will provide women in the U.S. with free evidence-based resources, rolled out in two phases. The first will focus on menopause and the second on migraine, with the overall goal of empowering women to take their health into their own hands.

Key Points: 
  • The first will focus on menopause and the second on migraine, with the overall goal of empowering women to take their health into their own hands.
  • When signing up for Rosy, each user takes a comprehensive Wellness Quiz, allowing Rosy to personalize an evidence-based, CBT-informed program with their unique concerns and priorities in mind.
  • While initially focused on sexual wellness, Rosy has expanded to include a wider range of women's health concerns, including endometriosis, PCOS, and more.
  • Physicians, providers, and hospital systems interested in recommending Rosy to their female patients are welcome to email [email protected] .

InventHelp Inventor Develops Massage Device to Relieve Headaches (ACC-240)

Retrieved on: 
Tuesday, April 16, 2024
Relaxation, Migraine, Sale, Pain, Suite, Massage, HEAD, Headache, Multimedia, Anxiety

PITTSBURGH, April 16, 2024 /PRNewswire/ -- "I thought there should be a hands-free way to massage the head to help relieve headache pain," said an inventor, from Loganville, Ga., "so I invented the HEAD, FOREHEAD, AND TEMPLE RELIEVER MASSAGER.

Key Points: 
  • PITTSBURGH, April 16, 2024 /PRNewswire/ -- "I thought there should be a hands-free way to massage the head to help relieve headache pain," said an inventor, from Loganville, Ga., "so I invented the HEAD, FOREHEAD, AND TEMPLE RELIEVER MASSAGER.
  • My design increases relaxation and comfort by quickly alleviating the pain and other symptoms associated with various types of headaches."
  • The patent-pending invention provides an effective means to relieve headaches.
  • In doing so, it helps diminish pain associated with minor headaches to intense migraines.

NYU Langone Neurologists Present Latest Clinical Findings & Research at AAN 2024

Retrieved on: 
Saturday, April 13, 2024
Neuroimaging, American Academy, Brain, MCI, Stroke, White matter, Risk, Professor, News, NYU Langone Health, Doctor of Philosophy, Research, Appreciation, NYU, Deficit spending, Patient, AAN, Neurosurgery, Headache, Prevalence, MRI, Job satisfaction, Faculty, DSM-IV codes, Philip, Traumatic brain injury, Migraine, Practice, Biomarker, Annual general meeting, Organization, Growth, Medical imaging

DENVER, April 13, 2024 /PRNewswire/ -- Experts from NYU Langone's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology (AAN) 2024 Annual Meeting, April 13 to 18, in Denver.

Key Points: 
  • DENVER, April 13, 2024 /PRNewswire/ -- Experts from NYU Langone's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology (AAN) 2024 Annual Meeting, April 13 to 18, in Denver.
  • U.S. News & World Report's "Best Hospitals" ranks NYU Langone the No.
  • Researchers at NYU Langone surveyed 90 clinicians, residents, and fellows to identify the best methods of showing neurologists that they are valued in order to improve their job satisfaction and reduce burnout.
  • Further research is warranted to validate these findings and their potential to enhance early detection and intervention strategies for Alzheimer's disease.

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine

Retrieved on: 
Friday, April 12, 2024
Patient, ABBV, Safety, AbbVie, MD, Migraine, Freedom, European, Disease, Week, CGRP, Anesthesia, Neurology, Headache, PROGRESS, Harvard Medical School, Interim, Pharmaceutical industry

NORTH CHICAGO, Ill., April 12, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine. The overall long-term safety results were consistent with the known safety profile of atogepant in chronic and episodic migraine, and no new safety signals were identified. These results also support improvements in key efficacy outcomes, including reduction in monthly acute medication use days.

Key Points: 
  • The overall long-term safety results were consistent with the known safety profile of atogepant in chronic and episodic migraine, and no new safety signals were identified.
  • These results also support improvements in key efficacy outcomes, including reduction in monthly acute medication use days.
  • Overall safety results were consistent with the known safety profile of atogepant 60 mg, and no new safety signals were identified.
  • "Patients should accept nothing less than migraine freedom, and the long-term safety and efficacy shown in this interim analysis marks another step toward that goal."